Comparative efficacy of biologics and small molecule drugs in treating pediatric atopic dermatitis in patients aged 2–18 years: A 12–16 week network meta‐analysis of randomized controlled trials

This analysis establishes a hierarchy of effectiveness among systemic therapies for pediatric AD, with upadacitinib showing highest efficacy. However, the predominance of adolescent data emphasizes the need for age-stratified studies in younger children and long-term safety assessments.